EPISODE · Jan 18, 2022 · 22 MIN
Episode #124 - Alzheimer's, Aduhelm & Medicare: What's Next?
from CareTalk: Healthcare. Unfiltered. · host CareTalk Podcast
Send us Fan MailAduhelm was the first new Alzheimer's treatment approved by the FDA in 18 years. However, its approval proved to be exceptionally controversial, as many medical experts and doctors opposed the drug, due to the lack of evidence that it is actually effective in slowing memory loss.In this episode, John and David discuss how Aduhelm got approved and the polarizing affect it is having on US healthcare as whole. Visit us at www.caretalkpodcast.comView this episode on YouTube: https://youtu.be/XGVC0E0XCxAFollow us on the Health Podcast Network: https://bit.ly/3Glciwj#healthcareindustry #healthcarepolicy #caretalkpodcast #aduhlem #alzheimers #medicareSupport the show⚙️CareTalk: Healthcare. Unfiltered. is produced by Grippi Media Digital Marketing Consulting.
Embed this episode
What this episode covers
Send us Fan Mail Aduhelm was the first new Alzheimer's treatment approved by the FDA in 18 years. However, its approval proved to be exceptionally controversial, as many medical experts and doctors opposed the drug, due to the lack of evidence that it is actually effective in slowing memory loss. In this episode, John and David discuss how Aduhelm got approved and the polarizing affect it is having on US healthcare as whole. Visit us at www.caretalkpodcast.com View this episode on YouTube...
NOW PLAYING
Episode #124 - Alzheimer's, Aduhelm & Medicare: What's Next?
No transcript for this episode yet
Similar Episodes
No similar episodes found.